Мы в Telegram
Добавить новость
smi24.net
Forbes.com
Декабрь
2018

Новости за 03.12.2018

Coal Power Plants Lose Their Cost Advantage Over Clean Energy

Forbes.com 

Renewable energy is now so cheap that it is more cost-effective to build new wind and solar farms than to run 42% of existing coal plants. By 2030, 96% of coal plants will be in that situation, bringing into question the rationale for building new coal-fired generating capacity.

Hanukkah And Eight Media Miracles We Could All Use

Forbes.com 

Hanukkah and its focus on one Godly miracle (8 days of an oil-burning lamp) provides a great opportunity to celebrate more terrestrial “miracles”, and to wish for some new ones to come our way. The media business in particular could use more than a few, and here is one man’s wish list.



Healthcare Startups Raised $2.2 Billion In November

Forbes.com 

Venture capital fundraising among healthcare startups was down 25% to $2.18 billion in November compared the same month one year ago, according to an analysis conducted for Forbes by Pitchbook.

Former Cisco CEO John Chambers Is Trying To Change The World

Forbes.com 

John Chambers is a native of West Virginia. In his new book, he notes that much of what he has achieved can be traced back to his childhood in that state. Now he hopes to bring his experience as a CEO to bear now as a venture capitalist to spur growth and entrepreneurship in that state and others.

60 Cybersecurity Predictions For 2019

Forbes.com 

60 predictions for cybersecurity in 2019 reveal the state-of-mind of key industry participants from artificial intelligence (AI) helping both attackers and defenders to data privacy, the cloud, IoT, and the emerging global cyber war conducted by terrorists, criminals, and nation-states.

How One AI Learning Tool Helps Oil Companies Reduce Costs

Forbes.com 

Times of increased price volatility in the oil patch place a premium on the ability of companies to constantly lower their costs structures. One service provider is helping companies achieve that goal through more accurate weather forecasts.

GSK Buys Tesaro For $5 Billion In Dramatic Bet On Cancer Genetics

Forbes.com 

The deal is a dramatic bet that the London-based drug giant can see opportunities connected to the genetics of cancer drugs better than the stock market. It fits into a framework outlined in July by Hal Barron, the widely respected pharma veteran who took over as GSK’s head of R&D last year.

Why Bunge Is A Buy

Forbes.com 

I think this is an excellent time for an investor to jump into Bunge, here's why.





СМИ24.net — правдивые новости, непрерывно 24/7 на русском языке с ежеминутным обновлением *